Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2 ...
An evolving understanding of the risks and benefits of HRT has led to a reevaluation of the role of HRT for breast cancer survivors.
NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor These results provide insights into ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Results from the OASIS 4 clinical trial show that a new drug, elinzanetant, relieved hot flashes and night sweats that can ...
The role of oestrogen receptor beta (ERβ) in breast cancer continues to be a subject of considerable scientific enquiry. Traditionally overshadowed by its counterpart, ERα, ERβ is now understood to be ...
Immune cells in the uterus shortly after mating. Panels A–F show CD45+ immune cells, and panels G–L show ELANE+ neutrophils at two time points: 0.5 days (D0.5) and 3.5 days (D3.5) after mating. (A, G) ...
Progesterone Receptor Positive (PR+) breast cancer is a distinct biological subtype of hormone receptor positive breast cancer. This type of cancer grows in response to progesterone, a hormone that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results